A. Ben-Jacob

Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial

Veena Charu, Chandra P. Belani, Ahmad N. Gill et al. · The Oncologist · 2007 · 32 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study

David Gordon, Gwen Nichols, A. Ben-Jacob et al. · The Oncologist · 2008 · 24 citations

Medicine, Hematology, Pharmacology +14

A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia

Veena Charu, Bruce Saidman, A. Ben-Jacob et al. · The Oncologist · 2007 · 19 citations · Full text

Medicine, Hematology, Pharmacology +13

Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA)

Timothy P. Rearden, Veena Charu, Bruce Saidman et al. · Journal of Clinical Oncology · 2004 · 19 citations

Medicine, Pharmacology, Pharmacotherapy +11

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David Gordon, Gwen Nichols, A. Ben-Jacob et al. · Blood · 2006 · 13 citations

Medicine, Oncology, Pharmacology +6